National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
HIV Med. 2020 Dec;21(11):701-707. doi: 10.1111/hiv.13020.
This study aimed to present the clinical characteristics of and viral suppression in the national antiretroviral therapy (ART) cohort in China.
A cross-sectional study was conducted among the participants enrolled in China's National Free Antiretroviral Therapy Programme (NFATP) who were on ART at the end of 2019. The data used were from China's NFATP information system. The primary outcome was viral load (VL) suppression. Full virological suppression and low-level viraemia (LLV) were defined as VL < 50 copies/mL and between 51 and 999 copies/mL, respectively.
At the end of 2019, 853 429 people living with HIV (PLWH) were on ART. The median age was 44 years [interquartile range (IQR): 33-54]. The majority of PLWH were 25-44 years old (47.2%) and male (73.5%) and reported HIV infection via heterosexual contact (64.5%). The median (IQR) baseline CD4 count was 257 (140-376) cells/μL. Among the 704 375 PLWH who were on ART for at least 12 months, 82.9% had full virological suppression, 6.5% had VL between 50 and 1000 copies/mL (LLV) and 4.3% had VL > 1000 copies/mL. Optimal full virological suppression occurred in participants who acquired HIV through homosexual contact (88.4%).
Although China can be credited for substantial progress in scaling up ART and viral suppression, challenges remain in some key populations, such as injecting drug users, participants with a history of treatment failure and hepatitis C virus co-infected people. To improve the programme output, additional monitoring and intervention for LLV are necessary.
本研究旨在介绍中国国家艾滋病抗病毒治疗(ART)队列的临床特征和病毒抑制情况。
本研究采用横断面研究,纳入 2019 年底正在接受国家免费艾滋病抗病毒治疗项目(NFATP)ART 的患者。数据来自中国 NFATP 信息系统。主要结局为病毒载量(VL)抑制。完全病毒学抑制和低水平病毒血症(LLV)定义为 VL<50 拷贝/ml 和 51-999 拷贝/ml。
2019 年底,共有 853429 名艾滋病毒感染者(PLWH)正在接受 ART。中位年龄为 44 岁[四分位距(IQR):33-54]。大多数 PLWH 年龄在 25-44 岁(47.2%),男性(73.5%),经异性性接触感染 HIV(64.5%)。中位(IQR)基线 CD4 计数为 257(140-376)个/μl。在 704375 名至少接受 12 个月 ART 的 PLWH 中,82.9%达到完全病毒学抑制,6.5%VL 为 50-1000 拷贝/ml(LLV),4.3%VL>1000 拷贝/ml。经同性性接触感染 HIV 的患者获得完全病毒学抑制的比例最高(88.4%)。
尽管中国在扩大 ART 和病毒抑制方面取得了重大进展,但在一些关键人群中仍存在挑战,如注射吸毒者、有治疗失败史者和丙型肝炎病毒合并感染者。为了提高项目效果,需要对 LLV 进行额外的监测和干预。